Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 169

1.

Complex genetics of Tourette's Syndrome: Piecing the puzzle.

Wagle Shukla A, Fox S.

Mov Disord. 2017 Nov 13. doi: 10.1002/mds.27218. [Epub ahead of print] No abstract available.

PMID:
29131391
2.

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.

Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS, Bochenek W, Tripp K, Currie MG, Fox SM, Blakesley RE, O'Dea CR, Omniewski ND, Hall ML.

Am J Gastroenterol. 2017 Aug 22. doi: 10.1038/ajg.2017.230. [Epub ahead of print]

PMID:
29091082
3.

Automated vision-based analysis of levodopa-induced dyskinesia with deep learning.

Li MH, Mestre TA, Fox SH, Taati B.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:3377-3380. doi: 10.1109/EMBC.2017.8037580.

PMID:
29060621
4.

A systematic review of interventions to foster physician resilience.

Fox S, Lydon S, Byrne D, Madden C, Connolly F, O'Connor P.

Postgrad Med J. 2017 Oct 10. pii: postgradmedj-2017-135212. doi: 10.1136/postgradmedj-2017-135212. [Epub ahead of print] Review.

PMID:
29018095
5.

Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Freitas ME, Hess CW, Fox SH.

Semin Neurol. 2017 Apr;37(2):147-157. doi: 10.1055/s-0037-1602423. Epub 2017 May 16. No abstract available.

PMID:
28511255
6.

Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

Huot P, Sgambato-Faure V, Fox SH, McCreary AC.

ACS Chem Neurosci. 2017 May 17;8(5):973-986. doi: 10.1021/acschemneuro.6b00440. Epub 2017 May 5.

PMID:
28460160
7.

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.

Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D, Chao R, Younes A.

Br J Haematol. 2017 Aug;178(3):434-441. doi: 10.1111/bjh.14698. Epub 2017 Apr 25.

8.

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.

Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J.

Mov Disord. 2017 Jun;32(6):893-903. doi: 10.1002/mds.26976. Epub 2017 Mar 30.

PMID:
28370447
9.

Patient Experience: Why It Is Important to Providers.

Fox S.

Front Health Serv Manage. 2017 Spring;33(3):42-48. doi: 10.1097/HAP.0000000000000004. No abstract available.

PMID:
28319982
10.

Integrating Patient Concerns into Parkinson's Disease Management.

Lim SY, Tan AH, Fox SH, Evans AH, Low SC.

Curr Neurol Neurosci Rep. 2017 Jan;17(1):3. doi: 10.1007/s11910-017-0717-2. Review.

PMID:
28102483
11.

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R.

JAMA Neurol. 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467.

PMID:
27942720
12.

Racial Differences in Food Allergy Phenotype and Health Care Utilization among US Children.

Mahdavinia M, Fox SR, Smith BM, James C, Palmisano EL, Mohammed A, Zahid Z, Assa'ad AH, Tobin MC, Gupta RS.

J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2):352-357.e1. doi: 10.1016/j.jaip.2016.10.006. Epub 2016 Nov 23.

PMID:
27888035
13.

Novel Levodopa Formulations for Parkinson's Disease.

Freitas ME, Ruiz-Lopez M, Fox SH.

CNS Drugs. 2016 Nov;30(11):1079-1095. Review.

PMID:
27743318
14.

Clinical and demographic characteristics related to onset site and spread of cervical dystonia.

Norris SA, Jinnah HA, Espay AJ, Klein C, Brüggemann N, Barbano RL, Malaty IA, Rodriguez RL, Vidailhet M, Roze E, Reich SG, Berman BD, LeDoux MS, Richardson SP, Agarwal P, Mari Z, Ondo WG, Shih LC, Fox SH, Berardelli A, Testa CM, Cheng FC, Truong D, Nahab FB, Xie T, Hallett M, Rosen AR, Wright LJ, Perlmutter JS.

Mov Disord. 2016 Dec;31(12):1874-1882. doi: 10.1002/mds.26817. Epub 2016 Oct 18.

15.

Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism.

Bruno VA, Fox SH, Mancini D, Miyasaki JM.

Can J Neurol Sci. 2016 Sep;43(5):697-702. doi: 10.1017/cjn.2016.279. Epub 2016 Aug 12.

PMID:
27514242
16.

Erratum to: Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Chang A, Fox SH.

Drugs. 2016 Sep;76(13):1319. No abstract available.

PMID:
27503375
17.

Patient Management Problem-Preferred Responses.

Fox SH.

Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1327-36. doi: 10.1212/01.CON.0000491170.82888.0b. No abstract available.

PMID:
27495214
18.

Patient Management Problem.

Fox SH.

Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1321-6. doi: 10.1212/CON.0000000000000361. No abstract available.

PMID:
27495213
19.

Treating the Motor Symptoms of Parkinson Disease.

Morgan JC, Fox SH.

Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1064-85. doi: 10.1212/CON.0000000000000355.

PMID:
27495198
20.

Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Chang A, Fox SH.

Drugs. 2016 Jul;76(11):1093-118. doi: 10.1007/s40265-016-0600-5. Review. Erratum in: Drugs. 2016 Sep;76(13):1319.

PMID:
27312429

Supplemental Content

Loading ...
Support Center